← Companies
Company
Sensorion
Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.
Programs
3
linked to organization
Strong Evidence
3
3 status confirmed
Details Checked
3
0 open data checks
Company / Institution Links
3 / 0
industry vs non-industry records
Competitive Density
4
Pipeline Velocity
70
Completion Signal
0
Programs by Stage
Preclinical1
Phase 1/21
Phase 21
Trial / Program Status
Active3
Modality Mix
Gene Therapy2
Small Molecule1
Indication Coverage
Hearing Loss3
Sensorineural Hearing Loss3
Genetic Hearing Loss2
Auditory Neuropathy1
Cisplatin-Induced Hearing Loss1
OTOF-Related Hearing Loss1
Sudden Sensorineural Hearing Loss1
Program Types
Therapeutic3
Population Tags
congenital2
genetic2
pre-lingual2
adult1
bilateral1
cisplatin-ototoxicity1
cochlear-implant1
otof-dfnb91
pediatric1
profound1
Strong-Evidence Records
3 recordsSENS-401 (Arazasetron) by Sensorion
Strong evidence
Small MoleculePhase 2Active
Oral R-azasetron besylate small molecule; Sensorion describes it as a 5-HT3 receptor antagonist and calcineurin inhibitor intended to protect and preserve inner-ear tissue from ototoxic and acute cochlear injury.
Data checks: topline-results-not-confirmed-after-2025-guidance
SENS-501 by Sensorion
Strong evidence
Gene TherapyPhase 1/2Active
Dual-AAV intracochlear gene therapy delivers otoferlin to restore hearing in OTOF deficiency.
GJB2-GT by Sensorion
Strong evidence
Gene TherapyPreclinicalActive
AAV-based gene therapy aims to restore connexin 26-related inner ear function in GJB2 hearing loss.